| ²é¿´: 2484 | »Ø¸´: 12 | ||||
Tina_1988ͳæ (³õÈëÎÄ̳)
|
[ÇóÖú]
ÇóÖúÀ´ÄÇÌæÄáÉÏÊÐÐÅÏ¢£¿ ÒÑÓÐ1È˲ÎÓë
|
|||
| ÔÚÍøÉÏ¿´µ½Óй«Ë¾¹ÒÀ´ÄÇÌæÄáÏîÄ¿ºÏ×÷ÐÅÏ¢£¬ÔÚCDEÉÏÓÐÀ´ÄÇÌæÄáÆ¬µÄ½ø¿ÚÉêÇ룬µ«ÊÇÎÒÈ´²é²»µ½¸ÃÒ©µÄ¾ßÌåÉÏÊÐÐÅÏ¢£¬ÌØ´ËÇóÖú£¬Íû´óÏÀÏà°ï£¬Ð»Ð»£¡ |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
ò§çïҩѧ |
» ²ÂÄãϲ»¶
Çó¹ºÊ±¼ä³¤Ò»Ð©µÄÏõËáîÊ
ÒѾÓÐ0È˻ظ´
²©µ¼ÍƼö
ÒѾÓÐ2È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ300È˻ظ´
ÄÄÀï×ö¸Ê°±ËáÊÜÌåÓëÅäÌå½áºÏÂʵÄÊÔÑé
ÒѾÓÐ0È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§Ôº×ÔÉíÃâÒß²¡¿ÎÌâ×éÕÐÊÕ»ù´¡Ò½Ñ§¡¢Ò©Ñ§ºÍÉúÎïѧµÈרҵµÄÑо¿Éú
ÒѾÓÐ7È˻ظ´
[ѧϰ×ÊÁÏ·ÖÏí] FAERSÊý¾Ý¿âµÄ²»Á¼·´Ó¦ÍÚ¾ò(ƵÊý·¨/±´Ò¶Ë¹·¨)
ÒѾÓÐ1È˻ظ´
ÕÐÊÕҽѧ¡¢»ù´¡Ò½Ñ§Ààµ÷¼ÁÑо¿Éú
ÒѾÓÐ0È˻ظ´
ÊÇ·ñÊôÓÚÆ¢ÉöÑôÐéÖ¤
ÒѾÓÐ0È˻ظ´
¹ØÓÚSCIÔÓÖ¾·¢±í¹ÒÃû
ÒѾÓÐ32È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§Ôº×ÔÉíÃâÒß²¡¿ÎÌâ×éÕÐÊÕ»ù´¡Ò½Ñ§Ïà¹Ø×¨ÒµµÄµ÷¼ÁÑо¿Éú
ÒѾÓÐ2È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÇóÖú°¢·¨ÌæÄáºÏ³ÉÎÄÏ×
ÒѾÓÐ7È˻ظ´
¡¾ÇóÖú¡¿FDA2012ÄêÅú×¼ÐÂÒ©°¢Î÷ÌæÄáµÄרÀû
ÒѾÓÐ7È˻ظ´
´ïÉ³ÌæÄáÉÏÊÐʱ¼ä£¿
ÒѾÓÐ8È˻ظ´
canertinib¿¨ÄÎÌæÄáÕâ¸ö¿¹Ö×ÁöÒ©ÎïÓÐûÓÐÉÏÊУ¿
ÒѾÓÐ4È˻ظ´
ÇóÖú°ÂÀÎ÷̹¹úÍâÉÏÊÐÐÅÏ¢
ÒѾÓÐ5È˻ظ´
¡¾ÇóÖú¡¿·²µÂËûÄᣨvandetanib£©µÄÉÏÊйú¼ÒºÍʱ¼ä¼°ÆäרÀûÇé¿ö
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú¡¿ÇëÎʲ»ÔÚÃÀ¹úÉÏÊеÄÒ©Îï¿ÉÒÔµ½Ê²Ã´µØ·½²éµ½Ò©Æ·Ñз¢ÐÅÏ¢£¿ÒÔ¼°×¨Àû£¿
ÒѾÓÐ5È˻ظ´
¡¾ÇóÖú¡¿¹úÍâÉÏÊÐÒ©Æ·µÄÐÅÏ¢
ÒѾÓÐ14È˻ظ´
¡¾ÇóÖú¡¿ÈçºÎ²éÈÕ±¾ÉÏÊеÄÒ©ÎïÐÅÏ¢
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú¡¿ÒÁÂíÌæÄáµÄÖÊÁ¿±ê×¼
ÒѾÓÐ8È˻ظ´
¡¾ÇóÖú¡¿ÈçºÎѰÕÒ¶àëÄÉÏÊÐÒ©ÎÓÐÄÄÐ©ÍøÕ¾£¿
ÒѾÓÐ11È˻ظ´
áEÓûÌÕÈ»
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ½ð±Ò: 3995.6
- É¢½ð: 25
- Ìû×Ó: 345
- ÔÚÏß: 263.5Сʱ
- ³æºÅ: 855206
- ×¢²á: 2009-09-23
- ÐÔ±ð: GG
- רҵ: ºÏ³ÉÒ©Îﻯѧ
|
Puma Biotechnology, under license from Pfizer (previously Wyeth), is developing neratinib (PB-272; HKI-272), an irreversible pan-HER (Erbb1, ErbB2 and ErbB4) tyrosine kinase inhibitor, for the potential oral treatment of HER2-positive cancers, primarily breast cancer In July 2009, worldwide phase III breast cancer trials were initiated by Wyeth in patients who had received prior trastuzumab-based therapy ; in October 2011, following its acquisition of rights, Puma intended to terminate the ongoing Pfizer-sponsored trials , and the company began its own phase III trial in third-line metastatic breast cancer in June 2013 . In July 2014, Puma planned to file the drug for approval in the extended adjuvant setting for breast cancer in 1H15 . Development in other HER2-positive cancer settings is ongoing. In April 2013, a phase II trial in patients with NSCLC was ongoing . In October 2013, a phase II study in patients with other solid tumors with a HER2 mutation was initiated ; in March 2014, initial data from the trial were expected in 2014 |

5Â¥2014-08-28 09:04:03
fepwjh7
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 14
- Ìû×Ó: 34
- ÔÚÏß: 4.9Сʱ
- ³æºÅ: 3299358
- ×¢²á: 2014-06-30
6Â¥2014-08-28 09:30:07
kdl0721
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 76 (³õÖÐÉú)
- ½ð±Ò: 528.3
- É¢½ð: 69
- ºì»¨: 30
- Ìû×Ó: 1047
- ÔÚÏß: 319Сʱ
- ³æºÅ: 1246356
- ×¢²á: 2011-03-27
- רҵ: ÎÞ»ú·Ç½ðÊô»ù¸´ºÏ²ÄÁÏ
|
¹úÄÚÉ걨½ø¿Ú¸úÉêÇëFDAºÍEMAÉÏÊв¢Ã»ÓÐÁªÏµ¡£nintedanibͬÑùÒ²ÊÇÉêÇë½ø¿ÚÁÙ´²£¬¶ønintedanibҲûÓÐÔÚFDAÉÏÊУ¬Ö»ÊDZ»FDAÊÚÓèÍ»ÆÆÐÔÁÆ·¨¡£ |
9Â¥2014-08-28 14:11:11
kdl0721
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 76 (³õÖÐÉú)
- ½ð±Ò: 528.3
- É¢½ð: 69
- ºì»¨: 30
- Ìû×Ó: 1047
- ÔÚÏß: 319Сʱ
- ³æºÅ: 1246356
- ×¢²á: 2011-03-27
- רҵ: ÎÞ»ú·Ç½ðÊô»ù¸´ºÏ²ÄÁÏ
2Â¥2014-08-27 16:55:56
Tina_1988
ͳæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 944.5
- Ìû×Ó: 10
- ÔÚÏß: 37.3Сʱ
- ³æºÅ: 2534673
- ×¢²á: 2013-07-06
- רҵ: ÓлúºÏ³É
3Â¥2014-08-27 16:58:18
kdl0721
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 76 (³õÖÐÉú)
- ½ð±Ò: 528.3
- É¢½ð: 69
- ºì»¨: 30
- Ìû×Ó: 1047
- ÔÚÏß: 319Сʱ
- ³æºÅ: 1246356
- ×¢²á: 2011-03-27
- רҵ: ÎÞ»ú·Ç½ðÊô»ù¸´ºÏ²ÄÁÏ
4Â¥2014-08-28 08:46:35
Tina_1988
ͳæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 944.5
- Ìû×Ó: 10
- ÔÚÏß: 37.3Сʱ
- ³æºÅ: 2534673
- ×¢²á: 2013-07-06
- רҵ: ÓлúºÏ³É
7Â¥2014-08-28 11:20:00
Tina_1988
ͳæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 944.5
- Ìû×Ó: 10
- ÔÚÏß: 37.3Сʱ
- ³æºÅ: 2534673
- ×¢²á: 2013-07-06
- רҵ: ÓлúºÏ³É
8Â¥2014-08-28 11:22:08
fishlone
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 50 (СѧÉú)
- ½ð±Ò: 9.7
- É¢½ð: 575
- ºì»¨: 5
- Ìû×Ó: 1427
- ÔÚÏß: 154.9Сʱ
- ³æºÅ: 1632307
- ×¢²á: 2012-02-21
- ÐÔ±ð: GG
- רҵ: Ò©¼Áѧ
|
Puma Biotechnology, under license from Pfizer (previously Wyeth), is developing neratinib (PB-272; HKI-272), an irreversible pan-HER (Erbb1, ErbB2 and ErbB4) tyrosine kinase inhibitor, for the potential oral treatment of HER2-positive cancers, primarily breast cancer In July 2009, worldwide phase III breast cancer trials were initiated by Wyeth in patients who had received prior trastuzumab-based therapy ; in October 2011, following its acquisition of rights, Puma intended to terminate the ongoing Pfizer-sponsored trials , and the company began its own phase III trial in third-line metastatic breast cancer in June 2013 . In July 2014, Puma planned to file the drug for approval in the extended adjuvant setting for breast cancer in 1H15 . Development in other HER2-positive cancer settings is ongoing. In April 2013, a phase II trial in patients with NSCLC was ongoing . In October 2013, a phase II study in patients with other solid tumors with a HER2 mutation was initiated ; in March 2014, initial data from the trial were expected in 2014 |
10Â¥2014-08-28 18:00:06














»Ø¸´´ËÂ¥